INMUNE BIO INC. — Revenue by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/9c4a550b-534b-4eb3-9382-766f5dd347d7/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $50.0k | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-036370 |
| FY 2024 | $14.0k | 2024-01-01 – 2024-12-31 | evidence 0001013762-25-003354 |
| FY 2023 | $155.0k | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-027206 |
| FY 2022 | $374.0k | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-016875 |
| FY 2021 | $181.0k | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-010573 |
| FY 2020 | $11.0k | 2020-01-01 – 2020-12-31 | evidence 0001213900-22-010573 |
| FY 2018 | $0 | 2018-01-01 – 2018-12-31 | evidence 0001640334-19-000466 |
| FY 2017 | $0 | 2017-01-01 – 2017-12-31 | evidence 0001640334-19-000466 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).